NCT07389772 (TLR9 in T2DM) is a clinical trial in Type 2 Diabetes, sponsored by bengisu yüksel.

Who is sponsoring NCT07389772?

NCT07389772 is sponsored by bengisu yüksel.

What condition does NCT07389772 study?

NCT07389772 studies Type 2 Diabetes.

Is NCT07389772 still recruiting?

NCT07389772 is currently enrolling by invitation. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT07389772: TLR9 in T2DM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

INVESTIGATION OF THE EFFECT OF DIFFERENT ACTIVATION TECHNIQUES ON TLR9, IL6, IL10, TNF-ALFA LEVELS IN HEALTHY AND TYPE 2 DIABETIC PATIENTS WITH APICAL PERIODONTITIS REQUIRING RETREATMENT

ENROLLING BY INVITATION Last updated 10 February 2026

What this trial tests

trial in Type 2 Diabetes in 90 participants. Enrolling by invitation.

Timeline

28 January 2026

Primary endpoint
30 June 2026

15 May 2027

Quick facts

Lead sponsor	bengisu yüksel
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	90
Start date	28 January 2026
Primary completion	30 June 2026
Estimated completion	15 May 2027
Sites	1 location across Turkey (Türkiye)

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

bengisu yüksel

Who can join

Adults 18 to 50, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The subject of this thesis study is the effects of SWEEPS laser and ultrasonic activation methods on the immune response in the treatment of apical periodontitis in healthy individuals and patients with Type 2 diabetes requiring retreatment, based on a comparative investigation of Toll-like Receptor 9 (TLR-9), Interleukin-6 (IL-6) and Tumour Necrosis Factor alpha (TNF-α), and Interleukin-10 (IL-10) levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07389772 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by bengisu yüksel
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07389772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing